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18–49 years were 57% less likely (OR 0.43 95% CI 0.41–0.46,
p < 0.0001), to receive antilipidemics than patients 65 years
old. Patients with substantial disease burden (Charlson Index >1)
were 9% more likely to receive antilipidemics (OR 1.09, 95% CI
1.01–1.18, p = 0.024) than those with no or moderate disease
burden (Charlson1). CONCLUSION: Although CHD remains
a leading cause of U.S.mortality irrespective of sex, race/ethnicity,
or age, and antilipidemics beneﬁt patients across these demo-
graphic characteristics, we found that females, Blacks, and
younger (aged 18–50 years) Medicaid patients with dyslipidemia
were signiﬁcantly less likely to receive antilipidemics than their
male, White or older counterparts.
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OBJECTIVES: The purpose of this study was to compare the
survival of patients admitted to different types of hospitals for
their ﬁrst acute myocardial infarction (AMI), and to assess how
the deﬁnition of failure and different variables affect the results.
METHODS: The analysis utilized the Victorian Admitted Epi-
sodes Data Set from 1996–2005, which contains data on all
patients admitted to acute private and public hospitals in the
state of Victoria, Australia. A hazard model was used to model
time to failure, which was deﬁned either as 30-day mortality, or
readmission for subsequent AMI. Hospitals were grouped into
one of ﬁve types and these were included as explanatory
variables. Other control variables, including AMI location,
co-morbidities, treatments, and demographics, were added to the
model one by one in order to determine their effect on survival,
and on the effect of hospital type on survival. RESULTS: The
impact and signiﬁcance of hospital type on survival depended
strongly on the deﬁnition of failure. Large teaching hospitals had
signiﬁcantly higher failure rates than all other hospital types
when failure was deﬁned as readmissions, while this ordering
was almost reversed when failure was deﬁned as 30-day mortal-
ity. Controlling for planned and unplanned treatments did not
signiﬁcantly affect these results. Including indices of socio-
economic status ampliﬁed the effects when failure was deﬁned as
readmissions, but had no signiﬁcant effect otherwise. Location of
AMI was signiﬁcant only when failure was deﬁned as 30-day
mortality, and improved the relative performance of large
regional base and suburban hospitals. All other variables were
generally similar in both models. CONCLUSION: The effect of
hospital type on survival depended strongly on the deﬁnition of
failure and somewhat on the inclusion of certain control vari-
ables. The results suggest that comparing the effects of hospital
type using patient outcomes requires careful consideration.
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OBJECTIVES: To evaluate degree of implementation of the
American and European guidelines related to the treatment as
secondary prevention, in the management of patients with acute
myocardial infarction with ST segment elevation (STEMI).
METHODS: Cross-sectional and multicentric study realized in
cardiology outpatient clinics in Spain. Physicians included con-
secutively outpatients over 18 years with STEMI happened
within 2 previous years. The guidelines of reference were the
American College of Cardiology/American Heart Association
(ACC/AHA 2004) and European Society of Cardiology (ESC
2003). Descriptive statistics and comparison of averages (“t” of
Student and Or of Mann-Whitney) and proportions (Chi-
squared) were realized with SAS package. RESULTS: A total
of 1439 out of 1588 patients were valid for analysis (90.6%).
A total of 80.3% were males, middle age were 62.4 years-
old (STD = 11.8) and the average BMI was of 27.8 Kg/m2
(STD = 3.7). The most frequent concomitant diseases were
hypertension (53.6%) and diabetes mellitus type II (28.5%). The
average of time after STEMI was 9.6 months (STD = 7.2). The
treatments more frequently used were statins (93.6%), aspirin
(93.2%) and beta-blockers (83.5%). The treatments used in
accordance with guidelines were antiaggregants/anticoagulants
(99.7% in both guidelines), statins (94.4% in ACC/AHA and
93.5% in ESC) and beta-blockers (83.5% in both guidelines),
staying in the second term ACE inhibitors/ARBs (78.2% ACC/
AHA and 59.7% ESC) and aldosterone antagonists (19.3%), this
one only recommended by the ACC/AHA. To summarize, 65.3%
(ACC/AHA) and 52.4% (ESC) of the patients were being treated
according guidelines. Regarding lifestyle factors, only 9.2%
(ACC/AHA) and 6.4% of patients followed the overall guide-
lines’ recommendations. CONCLUSION: This study shows a
low implementation of guidelines by Spanish physicians in man-
aging patients with STEMI, with more adherences to ACC/AHA
2004 than ESC 2003 guidelines. Treatment recommendations are
more followed than life-style recommendations. Based on this
study, actions are needed to increase adherence of Guidelines in
Spain.
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OBJECTIVES: Surveys evaluating plasma lipid goal attainment
in CHD patients prior to the updated European guidelines on
CVD prevention (Third Joint Task Force [TJTF]) showed that
hypercholesterolemia is inadequately treated. Limited data
accounts for the reasons behind this. The aim of this survey was
to evaluate the current use and efﬁcacy of lipid lowering drugs
(LLD), and to identify possible patient/physician characteristics
associated with failure to be at the TJTF guideline LDL-C target.
METHODS: An European multi-centre, cross sectional survey in
8 countries including patients on LLD for >3 months (stable
medication >6 weeks). One visit was scheduled for data collec-
tion including fasting lipids analysed by a central laboratory. In
all but 1 country physicians and patients ﬁlled in a questionnaire
about aspects of hypercholesterolemia and treatment. Data was
analysed centrally. Determination of individual LDL-C targets
followed 2003 TJTF guidelines including SCORE tables.
RESULTS: A total of 15,199 patients were recruited (14478
included in the ﬁnal analyses) with the following characteristics:
mean (SD) age 63.2 (11.3) yrs (45% females), waist circumfer-
ence 97.0 (13.3) cm. 62% had a history of hypertension, 18%
were smokers, 32% of the subjects had metabolic syndrome
(MS) according to the NCEPATP III criteria. Reason to prescribe
LLD: 67% primary prevention (PP), 33% secondary prevention
(SP) or familial hypercholesterolemia. 93% of the patients used
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